Daniela Ferrer Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniela Ferrer Gonzalez has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Sič
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
1 shared publication - Conor George
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA
1 shared publication - Nebojsa Nick Knezevic
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA
1 shared publication - Vasilis-Spyridon Tseriotis
Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 7HB, UK
1 shared publication
Latest Publications
- Open Access
- 5 September 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 141
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges
Cannabinoids have gained increasing attention as potential therapeutic agents in chronic pain management. Their mechanisms of action, mediated through CB1 and CB2 receptors, provide a pharmacological alternative to conventional analgesics. The evidence is strongest for neuropathic pain and multiple sclerosis-related spasticity, while the results for fibromyalgia, osteoarthritis, and musculoskeletal pain remain inconsistent. The average pain reduction is modest, often not exceeding 0.5–1.0 points on a 10-point scale, and therapeutic gains are offset by safety concerns. Quantitative data show that discontinuation rates range from 4.3% at low-dose CBD to 12.9% at high-dose CBD, compared with 3.5% on placebo, while nabiximols (THC + CBD spray) are associated with dizziness in 25% of patients, somnolence in 8%, and treatment discontinuation in 12%. High-dose CBD also carries a measurable risk of hepatotoxicity. Regulatory heterogeneity further constrains trial feasibility, scalability, and patient access, with disparities evident across the United States, Europe, Canada, and Australia. Overall, cannabinoids provide modest, condition-specific analgesia and should be considered adjunctive rather than first-line options, reserved for patients unresponsive to conventional therapy. Future progress requires standardized formulations, harmonized international regulations, long-term safety data, and large-scale randomized controlled trials to clarify their role in evidence-based pain management.
- 5 September 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 141
Open AccessCannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges
Cannabinoids have gained increasing attention as potential therapeutic agents in chronic pain management. Their mechanisms of action, mediated through CB1 and CB2 receptors, provide a pharmacological alternative to conventional analgesics. The evidence is strongest for neuropathic pain and multiple sclerosis-related spasticity, while the results for fibromyalgia, osteoarthritis, and musculoskeletal pain remain inconsistent. The average pain reduction is modest, often not exceeding 0.5–1.0 points on a 10-point scale, and therapeutic gains are offset by safety concerns. Quantitative data show that discontinuation rates range from 4.3% at low-dose CBD to 12.9% at high-dose CBD, compared with 3.5% on placebo, while nabiximols (THC + CBD spray) are associated with dizziness in 25% of patients, somnolence in 8%, and treatment discontinuation in 12%. High-dose CBD also carries a measurable risk of hepatotoxicity. Regulatory heterogeneity further constrains trial feasibility, scalability, and patient access, with disparities evident across the United States, Europe, Canada, and Australia. Overall, cannabinoids provide modest, condition-specific analgesia and should be considered adjunctive rather than first-line options, reserved for patients unresponsive to conventional therapy. Future progress requires standardized formulations, harmonized international regulations, long-term safety data, and large-scale randomized controlled trials to clarify their role in evidence-based pain management.